Table1 Patient characteristics.

From: Safety assessments and clinical features of PARP inhibitors from real-world data of Japanese patients with ovarian cancer

 

Olaparib (N = 131)

Niraparib (N = 50)

p value

Age

59 (30–80)

59 (23–80)

0.57

BMI

21.2 (14.2–32.8)

21.9 (14.3–30.4)

0.54

Smoking

14 (10.7%)

8 (16.0%)

0.59

Drinking

9 (6.9%)

10 (20.0%)

0.01

DM

9 (6.9%)

5 (10.0%)

0.53

Histologic subtype

 Serous

115 (87.8%)

32 (64.0%)

< 0.01

 Endometrioid

9 (6.9%)

6 (12.0%)

 Clear

5 (3.8%)

5 (10.0%)

 Carcinosarcoma

0 (0.0%)

1 (2.0%)

 Unknown

2(1.5%)

6 (12.0%)

BRCA status

 Positive

26 (19.8%)

2 (4.0%)

0.01

 Negative

36 (27.5%)

26 (52. 0%)

 Unknown

69 (52.7%)

22 (44. 0%)

HRD

 Positive

19 (14.5%)

4 (8.0%)

0.32

 Negative

2 (1.5%)

12 (24.0%)

 Unknown

110 (83.9%)

33 (66.0%)

  1. BMI, body mass index; DM, diabetes mellitus; HRD, homologous recombination deficiency.
Back to article page